Euroopa farmakopöa töökava asjus

1

Signe Leito

Saatja: [email protected] Saatmisaeg: neljapäev, 23. aprill 2026 12:58 Adressaat: Signe Leito Teema: Addition of Lisdexamfetamine dimesylate to the Ph. Eur. work programme:

EDQM-2026-02041-mail

Järeltegevuse lipp: Järeltegevus Olekulipp: Lipuga märgitud

Please make sure to include in any reply our mail reference: EDQM-2026-02041-mail **************************************************************************** European Pharmacopoeia Commission Secretariat

LETTER FOR THE ATTENTION OF NPAs Copy: Presidium Dear Colleagues,

Please find below the link to a survey being carried out concerning the proposed addition of Lisdexamfetamine dimesylate to the Ph. Eur. work programme.

In order to have access to the survey, please copy and paste this link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=553277&lang=en

Deadline for replies: 23 May 2026

With kind regards,

On behalf of Dr Jaume Sanz-Biset

Mireille Kopf Secretarial Assistant European Pharmacopoeia Department EDQM - Council of Europe Tel.: +33 (0)3 88 41 28 53 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://store.edqm.eu Stay connected with the EDQM

****************************************************************************

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.

2

Please make sure to include in any reply our mail reference: EDQM-2026-02041-mail